Low-molecular heparin in athero-thrombotic cardiovascular diseases: Its value in coronary heart diseases: Its value in coronary heart disease, ischaemic stroke and peripheral vascular disease;Niedermolekulare heparine bei atherothrombotischen kardiovaskularen erkrankungen: Stellenwert bei koronarer herzerkrankung, ischamischem schlaganfall und peripherer arterieller verschlulsskrankheit

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 25-26, 1999, Pages 802-809

  Stammler, Frank ^a   Diehm, C ^b  

^a Inn Abteilung des Sanakrankenhauses   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN RECEPTOR; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN; TROPONIN T; ANTICOAGULANT AGENT;

CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; PERIPHERAL VASCULAR DISEASE; REVIEW; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBOSIS;

ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; CORONARY DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOSIS;

EID: 0033603126     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024424     Document Type: Review

References (51)

1. 1 Armstrong, P. W.: Heparin in acute coronary disease. New Engl. J. Med. 337 (1997), 492-494.
2. 2 Badimon, L., B. J. Meyer, J. J. Badimon: Thrombin in arterial thrombosis. Haemostasis 24 (1994), 69-80.
3. 3 Bode, C., B. Kohler, M. Moser, R. Zimmermann, R. H. Strasser, W. Kübler: Antithrombotische Prävention und Therapie bei koronarer Herzerkrankung. Internist 38 (1997), 658-666.
4. 4 Boden, W. E., R. A. O'Rourke, M. C. Crawford, A. S. Blaustein, P. C. Deedwania, R. G. Zoble, L. F. Wexler, R. E. Kleiger, C. J. Pepine, D. R. Ferry, B. K. Chow, P. W. Lavori, for the Veterans Affairs Non-Q-Wave Infarctions Strategies in Hospital (VANQWISH) Trial Investigators; Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. New Engl. J. Med. 338 (1998), 1785-1792.
5. 5 Calabro, A., F. Piarulli, D. Milan, A. Rossi, G. Coscetti, G. Crepaldi: Clinical assessment of low molecular weight heparin effects in peripheral artery disease. Angiology 44 (1993), 188-195.
6. 6 Cairns, J. A., J. Gill, B. Morton, R. Roberts, M. Gent, J. Hirsh, D. Dolder, K. Finnie, J. F. Marquis, S. Naqvi, E. Cohen: Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 94 (1996), 1553-1560.
7. 7 Chamuleau, S. A., R. J. de Winter, M. Levi, R. Adams, H. R. Buller, M. H. Prins, K. I. Lie, R. J. Peters: Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin anticoagulant therapy in myocardial infarction Amsterdam (FATIMA) study group. Heart 80 (1998), 35-39.
8. 8 Charbonnier, B.: Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV study. Arch. Mal. Coeur Vaiss. 90 (1997), 1215-1221.
9. 9 Chinese Collaborative Group: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 349 (1997), 1641-1649.
10. 10 Cohen, M., P. C. Adams, G. Parry, J. Xiong, D. Chamberlain, I. Wieczorek, K. A. Fox, J. H. Chesebro, J. Strain, C. Keller: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end point analysis from the ATACS trial: Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 89 (1994), 81-88.
11. 11 Cohen, M., C. Demers, E. P. Gurfinkel, A. G. G. Turpie, G. J. Fromell, S. Goodman, A. Langer, R. M. Califf, K. Fox, J. Premmereur, F. Bigonzi, for the Efficacy and Safety of Subcutaneous Enoxiparin in Non-Q-Wave Coronary Events Study Group: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. New Engl. J. Med. 337 (1997), 447-552.
12. 12 Diener, H. C.: Primär-und Sekundärprävention des ischämischen Insultes. Dtsch. Ärztebl. 94 (1997), A-2195-2201.
13. 13 Edmondson, R. A., A. T. Cohen, S. K. Das, M. W. Wagner, V. V. Kakkar: Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 344 (1994), 914-918.
14. 14 Falk, E., P. K. Shah, V. Fuster: Coronary plaque disruption. Circulation 92 (1995), 657-671.
15. 15 Faxon, D. P., T. E. Spiro, S. Minor, G. Cote, J. Douglas, R. Gottlieb, R. Califf, K. Dorosti, E. Topol, J. B. Gordon: low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (REA) trial. Circulation 90 (1994), 908-914.
16. 16 Fragmin during Instability in Coronary Artery Disease (FRISC) study group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 347 (1996), 561-568.
17. 17 Fuster, V., L. Badimon, J. J. Badimon, J. H. Chesebro: The pathogenesis of conorary artery disease and the acute coronary syndromes. New Engl. J. Med. 326 (1992), 242-250.
18. 18 Glick, A., R. Kornowski, Y. Michowich, B. Koifman, A. Roth, S. Laniado, G. Keren: Reduction of reinfarction and angina with the use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Amer. J. Cardiol. 77 (1996), 1145-1148.
19. 19 Gurfinkel, E. P., E. J. Manos, R. I. Mejail, M. A. Cerda, E. A. Duronto, C. N. Garcia, A. M. Daroca, B. Mautner: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischaemia. J. Amer. Coll. Cardiol. 26 (1995), 313-318.
20. 20 Gurfinkel, E. P. on behalf of the Ushuaia Conference Group Coordinating Center. Current Treatment and future prospects for the management of acute coronary syndromes. Clin. Drug Invest. 15 (1998), 367-380.
21. 21 Gurfinkel, E. P. for the TMI 11B-study group: TIMI 11b-Studie. Symposium auf der 22. Herbsttagung der Deutschen Gesellschaft für Kardiologie, Leipzig 1998.
22. 22 Hamm, C. W., U. B. Goldmann, C. Heeschen, G. Kreymann, J. Berger, T. Meinertz: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. New Engl. J. Med. 337 (1997), 1648-1653.
23. 23 Harenberg, J., G. Huble, L. Piazolo, C. Giese, D. L. Heene: Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin. Thromb. Hemost. 23 (1997), 167-172.
24. 24 Jorneskog, G., K. Brismar, B. Fagrell: Low molecular weight heparin seems to improve local capillary circulation and healing of chronic ulcers in diabetic patients. Vasa 22 (1993), 137-142.
25. 25 Karsch, K. R., M. B. Preisack, R. Baildon, V. Eschenfelder, D. Foley, E. J. Garcia, M. Kaltenbach, C. Meisner, H. K. Selbmann, P. W. Serruys, M. F. Shiu, M. Sujatta, R. Bonan: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo controlled multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J. Amer. Coll. Cardiol. 28 (1996), 1437-1443.
26. 26 Kay, R., K. S. Wong, Y. Ling, Y. W. Chan, T. H. Tsoi, A. T. Ahuja, F. L. Chan, K. Y. Fong, C. B. Law, A. Wong, J. Woo: Low-molecular-weight heparin for the treatment of acute ischemic stroke. New Engl. J. Med. 333 (1995), 1588-1593.
27. 27 Klein, W., A. Buchwald, S. E. Hillis, S. Monrad, G. Sanz, A. G. Turpie, J. vander Meer, E. Olaisson, S. Undeland, K. Ludwig: Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation 96 (1997), 61-68.
28. 28 Kontny, F., J. Dale, U. Abildgaard, T. R. Pedersen: Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in acute myocardial infarction (FRAMI) study. J. Amer. Coll. Cardiol. 30 (1997), 962-969.
29. 29 Lablanche, J. M., E. P. McFadden, N. Meneveau, J. R. Lusson, B. Bertrand, J. P. Metzger, V. Legrand, G. Grollier, C. Macaya, B. de Bruyne, A. Vahanian, A. Grentzinger, C. Masquet, J. E. Wolf, G. Tobelem, S. Fontecave, A. Vacheron, P. d'Azemar, M. E. Bertrand: Effect of nadroparin, a low molecular weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine angioplastie coronaire transluminale. Circulation 96 (1997), 3396-3402.
30. 30 Lange, R. A., L. D. Hillis: Use and overuse of angiography and revascularisation for acute coronary syndromes. New Engl. J. Med. 338 (1998), 1838-1839.
31. 31 Laupacis, A., G. Albers, J. Dalen, M. I. Dunn, A. J. Jacobson, D. E. Singer: Antithrombotic therapy in atrial fibrillation. Chest 114 (1998), 579S-598S.
32. 32 Lindahl, B., P. Venge, L. Wallentin: Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J. Amer. Coll. Cardiol. 29 (1997), 43-48.
33. 33 Lowe, G. D., A. W. Reid, D. P. Leibermann: Management of thrombosis in peripheral arterial disease. Brit. med. Bull. 50 (1994), 923-935.
34. 34 Mannarino, E., L. Pasqualino, S. Innocente, U. Orlandi, V. Scriciolo, R. Lombardini, G. Ciufetti: Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology 42 (1991), 1-7.
35. 35 Mark, D.: When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial - an overview. Canad. J. Cardiol, 14 (1998), Suppl., 24E-27E.
36. 36 Melandri, G., F. Semprini, V. Cervi, N. Candiotti, A. Branzi, E. Palazzini, B. Magnani: Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Amer. J. Cardiol. 72 (1993), 450-454.
37. 37 Montalescot, G., F. Philippe, A. Ankri, R. Vicaut, E. Bearez, J. E. Poulard, D. Carrie, D. Flammang, A. Dutoit, C. Jardel, M. Chevrot, J. P. Bastard, F. Bigonzi, D. Thomas: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. French investigators of the ESSENCE trial. Circulation 98 (1998), 294-299.
38. 38 Stammler, F., C. Diehm: Niedermolekulare Heparine bei venöser Thromboembolie - Wirkmechanismus. Therapie und Prophylaxe. Dtsch. med. Wschr. 123 (1998), 604-611.
39. 39 Strandberg, L. E., T. Kahan, P. Lundin, J. Svensson, L. Erhardt: Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Haemostasis 26 (1996), 247-257.
40. 40 The Fraxiparin in ischemic syndromes study (FRAX.I.S.): Symposium auf dem Kongreßder European Society of Cardiology, Wien 1998.
41. 41 The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 345 patients with acute ischaemic stroke. International stroke trial collaborative group. Lancet 348 (1997), 1569-1581.
42. 42 The Platelet Receptor Inhibition in Ischemic Platelet Syndrome Management (PRISM) study investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl. J. Med. 338 (1998), 1498-1505.
43. 43 The Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl. J. Med. 338 (1998), 1488-1497.
44. 44 The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. J. Amer. med. Ass. 279 (1998), 1265-1277.
45. 45 The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial investigators: Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J. Amer. Coll. Cardiol. 29 (1997), 1474-1482.
46. 46 Théroux, P., H. Ouimet, J. McCans, J. G. Latour, P. Joly, G. Lévy, E. Pelletier, M. Juneau, J. Stasiak, P. de Guise, G. B. Pelletier, D. Rinzler, D. D. Waters: Aspirin, Heparin, or both to treat acute unstable angina. New Engl. J. Med. 319 (1988), 1105-1111.
47. 47 Théroux, P., D. Waters, J. Lam, J. McCans: Reactivation of unstable angina after the dicontinuation of heparin. New Engl. J. Med. 327 (1992), 141-145.
48. 48 Weitz, J.: Low-molecular-weight heparins. New Engl. J. Med. 337 (1997), 688-698.
49. 49 Wissler, R. W.: Update on the pathogenesis of atherosclerosis. Amer. J. Med. 91 (1991), 3S-9S.
50. 50 Wolf, P. A., R. D. Abbott, W. B. Kannel: Atrial fibrillation as an independent risk factor of stroke: the Framingham study. Stroke 22 (1991), 983-988.
51. 51 Zidar, J. P.: Low molecular weight heparin in coronary stenting. Canad. J. Cardiol. 14 (Suppl., 1998), 35E-39E.